The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective
- 9 February 2011
- journal article
- review article
- Published by Springer Nature in Child's Nervous System
- Vol. 27 (8) , 1203-1210
Abstract
Tuberous sclerosis (TSC) is a genetic multisystem disorder associated with hamartomas in several organs including subependymal giant cell tumors (SGCT). SGCT have the potential to grow and therefore to become symptomatic and are one of the main causes of death in TSC individuals. Surgical resection is the procedure of choice for SGCT. However, the discovery of mTOR pathway upregulation in TSC-associated tumors and recent evidence that mTOR inhibitors may induce regression of SGCT open up new treatment strategies. Based on a review of the currently available literature and on personal experience, current options for the management of TSC patients and appropriate indications, taking into account benefits and risks of surgery and pharmacotherapy, are discussed. An earlier diagnosis of SGCT in neurologically asymptomatic children may allow a precocious surgical removal of the tumor, thus minimizing surgery-related morbidity and mortality. Biologically targeted pharmacotherapy with mTOR inhibitors such as sirolimus and everolimus provides a safe and efficacious treatment option for patients with SGCT and has the potential to change the clinical management of these tumors. However, whether pharmacotherapy is sufficient to control growth or if it only delays the need for surgical removal of symptomatic SGCT remains unclear. Further studies are needed to determine the optimal levels of mTOR inhibitors that preserve maximal anti-tumor efficacy while minimizing side effects.Keywords
This publication has 52 references indexed in Scilit:
- Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complexJournal of neurosurgery. Pediatrics, 2010
- Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumorsJournal of Translational Medicine, 2010
- Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosisMolecular Cancer, 2009
- Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical modelsBMC Pharmacology, 2009
- Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis ComplexJournal of Child Neurology, 2008
- Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and FunctionThe Journal of Neuroscience, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- SUBEPENDYMAL GIANT-CELL ASTROCYTOMASIN PEDIATRIC TUBEROUS SCLEROSIS DISEASENeurosurgery, 2007
- Tuberous Sclerosis Consensus Conference: Recommendations for Diagnostic EvaluationJournal of Child Neurology, 1999
- A Neonatal Huge Subependymal Giant Cell AstrocytomaNeurosurgery, 1994